A novel intergenic region ALK fusion is targetable by alectinib in a non-small cell lung cancer patient with brain metastasis

Anaplastic lymphoma kinase (ALK) rearrangement defines a unique nonsmall cell lung cancer (NSCLC) molecular subtype, of which the patients could potentially benefit from anti-ALK therapies. So far, the outcomes of the canonical echinoderm microtubule-associated protein-like (EML-ALK) patients subjec...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Wanwan, Qian, Chunfa, Zhang, Haitao, Meng, Qi, Yin, Jiani C., Fang, Shencun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575568/
https://www.ncbi.nlm.nih.gov/pubmed/35946559
http://dx.doi.org/10.1097/CAD.0000000000001363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575568/
https://www.ncbi.nlm.nih.gov/pubmed/35946559
http://dx.doi.org/10.1097/CAD.0000000000001363

Ejemplares similares